Loading...
Antinicotine vaccines have been developed because of the low response and high relapse rates associated with currently available antinicotine replacement (pharmacological or psychotherapeutic) approaches. In theory, the vaccines, which attach nicotine to peripheral antibodies, would block nicotine from reaching the brain and would increase dopamine levels. However, the vaccines have had variable and unpredictable immunological effects. The current investigators developed a vaccine using an adeno-associated viral (AAV) vector that expresses a large amount of persistent antibodies to nicotine.
Nonaddicted mice received single administrations of the AAV vaccine or placebo. Both experimental and control mice then received repeated parenteral dos…